Bowie Capital Management LLC Has $223,000 Stock Holdings in Alto Neuroscience, Inc. (NYSE:ANRO)

Bowie Capital Management LLC decreased its stake in Alto Neuroscience, Inc. (NYSE:ANRO) by 54.9% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 19,484 shares of the company’s stock after selling 23,702 shares during the period. Alto Neuroscience comprises 0.0% of Bowie Capital Management LLC’s holdings, making the stock its 29th largest position. Bowie Capital Management LLC’s holdings in Alto Neuroscience were worth $223,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. bought a new position in shares of Alto Neuroscience during the first quarter worth $8,233,000. Price T Rowe Associates Inc. MD acquired a new stake in Alto Neuroscience during the 1st quarter worth $9,788,000. AWM Investment Company Inc. bought a new position in Alto Neuroscience during the first quarter worth about $4,592,000. Zimmer Partners LP acquired a new position in Alto Neuroscience in the first quarter valued at about $1,151,000. Finally, Artal Group S.A. bought a new stake in shares of Alto Neuroscience in the first quarter worth about $5,372,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ANRO shares. Wedbush lowered Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Stifel Nicolaus dropped their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. RODMAN&RENSHAW lowered shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, Rodman & Renshaw cut shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Stock Up 2.1 %

Shares of ANRO stock traded up $0.09 during trading on Monday, reaching $4.40. The company’s stock had a trading volume of 17,941 shares, compared to its average volume of 374,026. Alto Neuroscience, Inc. has a one year low of $3.61 and a one year high of $24.00. The business has a fifty day moving average price of $8.77 and a 200-day moving average price of $10.92. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. Analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.